高清福利片

As AstraZeneca is听听the preferred vaccine for Australian adults under 50, attention is turning to what other COVID-19 vaccine options are in our arsenal.

The federal government has ordered听听of the Pfizer vaccine, which will become the mainstay of the rollout, while AstraZeneca will continue to be administered for people over 50 in听.

The federal government also this week听听using Johnson & Johnson鈥檚 one-shot vaccine.

But Australia does have a deal for a third vaccine, by US biotech company Novavax. The government has ordered听, though it鈥檚 yet to be approved by Australia鈥檚 drug regulator, the Therapeutic Goods Administration (TGA), which is expected to make a decision in the听听.

At this stage, Novavax would be made offshore and imported, although Melbourne-based biotech CSL can make the vaccine听.

The Novavax vaccine is given as two doses, similar to the Pfizer and AstraZeneca shots already being used in Australia.

It can be stored for听听at fridge temperature, which differs from the Pfizer mRNA vaccine which needs to be kept at听. In saying that, the TGA听听the Pfizer vaccine can be stored at normal freezer temperatures for two weeks during transport, and at fridge temperatures for five days 鈥� though must still be kept ultra-cold after transport and in the long-term.

The vaccine also uses a different technology to the Pfizer and AstraZeneca vaccines. It鈥檚 a 鈥溾�� vaccine; these are vaccines that introduce a part of the virus to the immune system, but don鈥檛 contain any live components of the virus.

The protein part of the vaccine is the coronavirus鈥� 鈥溾��. This is part of the other COVID-19 vaccines in use but in a different form.

The Novavax vaccine uses a version of the spike protein made in the lab. The spike proteins are assembled into tiny particles called 鈥渘anoparticles鈥� which aim to resemble the structure of the coronavirus, however they cannot replicate once injected and the vaccine cannot cause you to get COVID-19.

In order for these subunit vaccines to generate strong protective responses, they need to include molecules that boost your immune system, called 鈥渁djuvants鈥�. The goal of these adjuvants is to mimic the way the real virus would activate the immune system, to generate maximum protective immunity.

Novavax includes an adjuvant听, an extract from the bark of the Chilean soapbark tree.

The interim data from phase 3 testing, released in March, was very encouraging. When tested in the UK in a clinical trial including more that 15,000 people, the vaccine was听听for those infected with the original strain of the coronavirus.

This compares well to the Pfizer vaccine, with an efficacy of 95%, and听听from AstraZeneca demonstrating 76% efficacy against COVID-19.

The Novavax vaccine is also safe. In听听the vaccine caused mainly mild adverse events such as pain and tenderness at the injection site, and no serious adverse reactions were recorded. In the larger trials, adverse events听听and were similar between the vaccine and placebo groups.

In the UK trial, the vaccine maintained strong protection against disease in people infected with the B.1.1.7 鈥淯K variant鈥�, demonstrating听.

This is good news because the B.1.1.7 variant is听, is听听than the original SARS-CoV-2 virus, and is responsible for most of the cases that have听.

Less encouraging is protection against the B.1.351 variant first identified in South Africa, which can听听that developed in response to earlier versions of the virus. The efficacy of Novavax鈥檚 shot听听in protecting against COVID-19 symptoms from this variant. Protection against severe disease however was 100%, indicating the vaccine will still be important in reducing hospitalisation and death due to this variant.

Novavax, along with the other major vaccine companies, are developing听听vaccines to target the B.1.351 variant. Novavax are听听a 鈥渂ivalent鈥� vaccine, which targets two different strains, using the spike protein from both the original Wuhan strain and the B.1.351 variant.

This article, which was first published in , was written by Professor Jamie Triccas, Professor of Medical Microbiology in the Faculty of Medicine and Health at the University of Sydney. Professor Triccas receives funding from the National Health and Medical Research Council (NHMRC).听

Professor Triccas is not involved in the review or approval of the Novavax vaccine in Australia. This article was written as an explainer piece only.听